Ftse Mib
33.968,78
1,01%
DAX
18.175,21
1,01%
S&P 500
5.161,85
0,66%
NASDAQ
16.268,76
0,70%
Bitcoin
63.055,98
-1,47%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni Regno Unito LSE Selvita Sa (0RKT) Selvita Sa (0RKT) Notizie

0RKT

Selvita (0RKT)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:LSE:0RKT
DataOraFonteTitoloSimboloCompagnia
06/03/202410:40UK RegulatoryRyvu Therapeutics to Present Preclinical Data on RVU120 and Synthetic Lethality Programs at the 2024 AACR Annual MeetingLSE:0RKTSelvita Sa
14/02/202419:12UK RegulatoryRyvu Announces Dosing of the First Patient in the RIVER-52 Phase II Study of RVU120 as a Monotherapy for the Treatment of Patients with Relapsed/Refractory AML and HR-MDSLSE:0RKTSelvita Sa
02/11/202316:02PR Newswire (US)Ryvu Therapeutics to Present Data on RVU120 at the 2023 American Society of Hematology (ASH) Annual MeetingLSE:0RKTSelvita Sa
28/09/202219:17PR Newswire (US)Ryvu Therapeutics Reports 2022 Half-Year Financial Results and Provides Corporate UpdateLSE:0RKTSelvita Sa
10/06/202211:54PR Newswire (US)Ryvu Therapeutics Presents Updated Clinical and Preclinical Data on RVU120 at the 2022 European Hematology Association (EHA) CongressLSE:0RKTSelvita Sa
08/03/202222:50PR Newswire (US)Ryvu Therapeutics to Present Data from its Oncology Programs at AACR 2022 Annual MeetingLSE:0RKTSelvita Sa
11/06/202110:30PR Newswire (US)Ryvu Therapeutics Presents Positive Phase I Data for RVU120 at the Virtual 26th Annual Congress of the European Hematology As...LSE:0RKTSelvita Sa
28/05/202114:08PR Newswire (US)Ryvu Therapeutics got full approval to conduct Phase I/II study of RVU120 (SEL120) in patients with relapsed/refractory metas...LSE:0RKTSelvita Sa
04/01/202122:05PR Newswire (US)Selvita completes acquisition of Fidelta from GalapagosLSE:0RKTSelvita Sa
01/12/202013:10PR Newswire (US)Three Posters on SEL24/MEN1703 including Pharmacodynamic Data from the Dose Escalation Part of DIAMOND-01 Trial to be publish...LSE:0RKTSelvita Sa
10/09/202012:51PR Newswire (US)Selvita reports strong financial results for H1 2020 and a record backlogLSE:0RKTSelvita Sa
10/06/202018:58PR Newswire (US)Ryvu Therapeutics Reports First Quarter 2020 Financial ResultsLSE:0RKTSelvita Sa
02/06/202016:20PR Newswire (US)Ryvu Therapeutics Has Completed the Construction of the R&D Center for Innovative DrugsLSE:0RKTSelvita Sa
26/05/202008:24PR Newswire (US)Selvita Reports Financial Results for Q1 2020: Dynamic Increase in Backlog for 2020 and Strong Position on the MarketLSE:0RKTSelvita Sa
14/05/202015:30PR Newswire (US)Ryvu Therapeutics Announces Availability of Abstracts Regarding Phase 1/2 Study of SEL120 and SEL24/MEN1703 Accepted for Pres...LSE:0RKTSelvita Sa
27/04/202009:33PR Newswire (US)Selvita and Ardigen Will Receive Funding for the Development of an AI-based High-content Screening PlatformLSE:0RKTSelvita Sa
16/04/202008:12PR Newswire (US)Galapagos and Ryvu Announce Research CollaborationLSE:0RKTSelvita Sa
27/02/202012:00PR Newswire (US)Ryvu Therapeutics to Present Recent Data From Multiple Oncology Programs at AACR 2020 Annual MeetingLSE:0RKTSelvita Sa
07/11/201912:30PR Newswire (US)Selvita Q3 2019 Results: Accelerated Growth, 45 Percent Increase in Commercial Revenues and Strong Long-term OutlookLSE:0RKTSelvita Sa
06/11/201917:39PR Newswire (US)Ryvu Therapeutics Announces Presentations on CDK8 Inhibitor SEL120 at the 61st ASH Annual MeetingLSE:0RKTSelvita Sa
06/11/201914:00PR Newswire (US)Ryvu Therapeutics Reports Third Quarter 2019 Financial ResultsLSE:0RKTSelvita Sa
01/10/201916:00PR Newswire (US)Ryvu Therapeutics and Selvita Announce Registration of Corporate Split by the National Court Register of PolandLSE:0RKTSelvita Sa
06/09/201908:00PR Newswire (US)Selvita Announces First Patient Dosed in Phase 1b Study of CDK8 Inhibitor SEL120 in the Treatment of Acute Myeloid Leukemia o...LSE:0RKTSelvita Sa
05/09/201908:00PR Newswire (US)Selvita Reports Second Quarter and Half-year 2019 Financial ResultsLSE:0RKTSelvita Sa
03/09/201919:00PR Newswire (US)Polish Financial Supervision Authority Approves Selvita CRO Prospectus, Allowing Corporate Split Into Two Separately Listed C...LSE:0RKTSelvita Sa
03/09/201911:00PR Newswire (US)Selvita to Present at Upcoming Conferences in SeptemberLSE:0RKTSelvita Sa
25/07/201908:00PR Newswire (US)Selvita Appoints Setareh Shamsili, M.D., Ph.D., as Chief Medical OfficerLSE:0RKTSelvita Sa
22/05/201907:30PR Newswire (US)Selvita Reports First Quarter 2019 Financial Results and Provides Corporate UpdateLSE:0RKTSelvita Sa
13/05/201913:00PR Newswire (US)Selvita to Present at the UBS 2019 Global Healthcare Conference in New YorkLSE:0RKTSelvita Sa
28/03/201912:43PR Newswire (US)Selvita to Separate Oncology Therapeutics and Contract Research Business Units Into Two Global CompaniesLSE:0RKTSelvita Sa
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:LSE:0RKT

La tua Cronologia

BIT
ISP
Intesa Sanpaolo
BIT
UCG
Unicredit
BIT
ENEL
Enel
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
STLAM
Stellantis NV
BIT
RACE
Ferrari NV
BIT
AMP
Amplifon
BIT
ENI
Eni
BIT
LDO
Leonardo
BIT
STMMI
ST Microelectronics
BIT
TEN
Tenaris
BIT
BPE
Bper Banca
BIT
BAMI
Banco BPM
BIT
SPM
Saipem
BIT
TIT
Telecom Italia
BIT
TRN
Terna Trasmissione Elett...
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network